Novel imaging techniques reshape the landscape in high-risk prostate cancers

Current Opinion in Urology

Volumn 23, Issue 4, 2013, Pages 323-330

  Lecouvet, Frederic E ^a   Lhommel, Renaud ^b   Pasoglou, Vasiliki ^a   Larbi, Ahmed ^a   Jamar, François ^b   Tombal, Bertrand ^c  

^a Radiology Department   (Belgium)

^b Nuclear Medicine Division   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

bone metastases; lymph node metastasis; magnetic resonance imaging; positron emission tomography; prostate cancer; staging; technetium bone scan

Indexed keywords

CHOLINE C 11; CHOLINE F 18; FLUORINE 18; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE F 18; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

BONE METASTASIS; BONE SCINTISCANNING; CANCER RISK; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYCLOTRON; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; IMAGING; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY;

BONE NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; KALLIKREINS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880135810     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328361d451     Document Type: Review

References (52)

1. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012; 61:1096-1106.
2. Verhagen PC, Schroder FH, Collette L, Bangma CH. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 2010; 58:261-269.
3. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24:1868-1876.
4. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378:2104-2111.
5. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373:301-308.
6. Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013; 11:27-32.
7. Jilg CA, Rischke HC, Reske SN, et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012; 188:2190-2197.
8. Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011; 60:935-943.
9. Moghanaki D, Koontz BF, Karlin JD, et al. Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. Cancer 2013; 9: 52-60.
10. Hansen J, Rink M, Bianchi M, et al. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. Prostate 2013; 73:211-218.
11. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113:2478-2487.
12. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197.
13. Vinjamoori AH, Jagannathan JP, Shinagare AB, et al. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol 2012; 199:367-372.
14. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1. Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59:61-71.
15. Clinical practice guidelines in oncology. Prostate cancer. V.1. 2013. [database on the Internet]. 2013. [cited 1 December 2012]. Available from http://www.nccn.org/professionals/physician-gls/PDF/prostate.pdf.
16. Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55:1251-1265.
17. Hovels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63:387-395.
18. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499.
19. Triantafyllou M, Studer UE, Birkhauser FD, et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer 2013; 49:616-624.
20. Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. Radiographics 2009; 29:1797-1810.
21. 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011; 60: 125-130.
22. Lecouvet FE, El Mouedden J, Collette L, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012; 62:68-75.
23. Cimitan M, Bortolus R, Morassut S, et al. [18F]Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33:1387-1398.
24. Poulsen MH, Bouchelouche K, Hoilund-Carlsen PF, et al. [(18)F]Fluoro-methylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 2012; 110:1666-1671.
25. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54:392-401.
26. Evangelista L, Guttilla A, Zattoni F, Muzzio PC. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2012 [Epub ahead of print]. doi: 10.1016/j.eururo.2012.09.039.
27. 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 2012; 37:325-331.
28. Giovacchini G, Picchio M, Garcia-Parra R, et al. [(11)C]Choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol 2013; 189:105-110.
29. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59:51-60.
30. 11C-Choline PET/CT for prostate cancer patients with biochemical recurrence following initial treatment. J Urol 2013; 189:1308-1313.
31. Detti B, Scoccianti S, Franceschini D, et al. Predictive factors of [18F]-choline PET/CT in 170 patients with increasing PSA after primary radical treatment. J Cancer Res Clin Oncol 2013; 139:521-528.
32. Gosfield E 3rd, Alavi A, Kneeland B. Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med 1993; 34:2191-2198.
33. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008; 49:68-78. [review].
34. 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297.
35. Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 2012; 199:1114-1120.
36. Lecouvet F, Simoni P, VandeBerg B, et al. Détection des métastases osseuses: l'IRM comme alternative à la scintigraphie osseuse. Onco 2008; 2:93-97.
37. Lecouvet FE, Simon M, Tombal B, et al. Whole-body (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 2010; 20:2973-2982.
38. Venkitaraman R, Cook GJ, Dearnaley DP, et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 2009; 53:241-247.
39. Tombal B, Rezazadeh A, Therasse P, et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005; 65:178-187.
40. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001; 177:229-236.
41. Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007; 25:3281-3287.
42. Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248:254-263.
43. 11C-choline. J Nucl Med 2011; 52:81-89.
44. Yi CA, Shin KM, Lee KS, et al. Nonsmall cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008; 248:632-642.
45. 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007; 46:161-168; quiz N47-N48.
46. Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 2007; 6:211-224.
47. Komori T, Narabayashi I, Matsumura K, et al. 2-[Fluorine-18]-fluoro-2- deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007; 21:209-215.
48. 11C-choline PET/CT for detection of bone metastases. Radiology 2008; 249:1017-1025.
49. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines. Eur Radiol 2012; 22:746-757.
50. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59:477-494.
51. 111In-capromab pendetide SPECT/CT. Radiology 2011; 259:852-861.
52. 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39:1085-1086.